Prescribing information

ENTRESTO (sacubitril/valsartan)'s Mechanism of Action (MoA)

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).¹

For further information, please refer to the Entresto Summary of Product Characteristics

ENTRESTO is a first-in-class ARNI with a dual MoA targeting two essential pathways in a complementary manner.¹

Watch the MoA video below to gain a deeper understanding of ENTRESTO’s complementary actions¹

Summary of the safety profile

The most commonly reported adverse events (AEs) during treatment with ENTRESTO were hypotension (17.6%), hyperkalaemia (11.6%) and renal impairment (10.1%). Angioedema was reported in patients treated with sacubitril/valsartan (0.5%).¹

Very common AEs:
Hyperkalaemia, hypotension, renal impairment.¹

Common AEs:
Anaemia, hypokalaemia, hypoglycaemia, dizziness, headache, syncope, vertigo, orthostatic hypotension, cough, diarrhoea, nausea, gastritis, renal failure (renal failure, acute renal failure), fatigue, asthenia.¹

Adverse reactions are ranked by system organ class and then by frequency with the most frequent first, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

ACEi, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; HFrEF, heart failure with reduced ejection fraction; RAAS, renin-angiotensin-aldosterone system.

References:

1. ENTRESTO (sacubitril/valsartan) Summary of Product Characteristics.

UK | April 2025 | FA-11282312